A study of women\u27s preferences regarding the formulation of over-the-counter vaginal spermicides by Coggins, Christiana et al.
Population Council
Knowledge Commons
Reproductive Health Social and Behavioral Science Research (SBSR)
1998
A study of women's preferences regarding the
formulation of over-the-counter vaginal
spermicides
Christiana Coggins
Christopher J. Elias
Ronachai Atisook
Mary T. Bassett
Virginie Ettiegne-Traore
See next page for additional authors
Follow this and additional works at: https://knowledgecommons.popcouncil.org/
departments_sbsr-rh
Part of the Demography, Population, and Ecology Commons, Family, Life Course, and Society
Commons, and the International Public Health Commons
This Report is brought to you for free and open access by the Population Council.
Recommended Citation
Coggins, Christiana, Christopher J. Elias, Ronachai Atisook, Mary T. Bassett, Virginie Ettiegne-Traore, Peter D. Ghys, Laura Jenkins-
Woelk, Earmporn Thongkrajai, and Nancy L. VanDevanter. 1998. "A study of women's preferences regarding the formulation of over-
the-counter vaginal spermicides," Robert H. Ebert Program on Critical Issues in Reproductive Health Publication Series. New York:
Population Council.
Authors
Christiana Coggins, Christopher J. Elias, Ronachai Atisook, Mary T. Bassett, Virginie Ettiegne-Traore, Peter
D. Ghys, Laura Jenkins-Woelk, Earmporn Thongkrajai, and Nancy L. VanDevanter
This report is available at Knowledge Commons: https://knowledgecommons.popcouncil.org/departments_sbsr-rh/497
==
 
 
 
 
 
 
 
A Study of Women’s Preferences 
 
Regarding the Formulation of  
 
Over-the-Counter Vaginal Spermicides 
 
 
 
==
 
 
 
 
 
 
 
 
A Study of Women’s Preferences 
 
Regarding the Formulation of  
 
Over-the-Counter Vaginal Spermicides 
   
 
 
Christiana Coggins1 
Christopher J.  Elias2 
Ronachai Atisook3 
Mary T. Bassett4 
Virginie Ettiègne-Traoré5 
Peter D. Ghys5/6 
Laura Jenkins-Woelk4 
Earmporn Thongkrajai7 
Nancy L. VanDevanter8 
 
 
 
 
 
1Population Council, New York, NY, USA 
2Population Council, Bangkok, Thailand 
3Siraraj Family Health Research Center, Bangkok, Thailand 
4University of Zimbabwe, Harare, Zimbabwe 
5Projet RETRO-CI, Abidjan, Côte d'Ivoire 
6Institute of Tropical Medicine, Antwerp, Belgium 
7Khon Kaen University, Khon Kaen, Thailand 
8Columbia University School of Public Health, New York, NY, USA  
 
==
The Population Council is an international, nonprofit, nongovernmental institution that 
seeks to improve the wellbeing and reproductive health of current and future generations 
around the world and to help achieve a humane, equitable, and sustainable balance 
between people and resources. The Council conducts biomedical, social science, and 
public health research and helps build research capacities in developing countries.  
 
The Council’s Robert H. Ebert Program on Critical Issues in Reproductive Health, 
established in 1988, responds to an awareness that many important reproductive health 
problemsand the ways women experience themhave been neglected by policy-
makers, program planners, and practitioners. Currently the Program focuses on several 
areas that merit special attention: improving the quality of services in reproductive health 
programs, managing unwanted pregnancy and preventing the consequences of unsafe 
abortion, devising new approaches to postpartum care to meet the health needs of the 
mother and child, and designing programs that address sexually transmitted diseases, 
including AIDS, within the larger context of women’s reproductive health. 
=
=
=
The Robert H. Ebert Program  
on Critical Issues in Reproductive Health 
Population Council 
One Dag Hammarskjold Plaza 
New York, NY  10017  USA 
(212) 339-0500 
Fax: 212-755-6052 
 
©1998 by The Population Council, Inc. 
 
 
Cover and text printed on recycled paper in the USA 
 
 
==
Acknowledgments 
 
This publication was made possible through the Office of Population, Center for 
Population, Health & Nutrition, Bureau for Global Programs, Field Support and 
Research, United States Agency for International Development, Cooperative Agreement 
No. CCP-3050-A-00-4013-00.  The opinions expressed herein are those of the authors 
and do not necessarily reflect the views of the U.S. Agency for International 
Development. 
 
We would like to express our appreciation to Charlotte Ellertson, Shelley Clark, Jessica 
Bull, Martha Brady, and Erica Gollub for their input into the study design, analysis and 
interpretation of findings. 
 
Author responsible for correspondence: 
 
Christiana Coggins, MPH 
Staff Associate 
Population Council 
The Robert H. Ebert Program on 
Critical Issues in Reproductive Health 
One Dag Hammarskjold Plaza 
New York, NY  10017 
 
 
 
 
 
 
 
==
ABSTRACT 
 
Objective:  There is an urgent need for safe, effective and acceptable vaginal barrier 
methods for the prevention of sexually transmitted diseases (STDs), including HIV.  A 
variety of existing spermicides have the potential to be used both for prevention of STDs 
and unwanted pregnancy.  Unfortunately, very little is known about formulation 
preferences and the desirable characteristics of vaginal preparations among the diverse 
populations of women who would potentially use these products.  As product 
acceptability ultimately determines compliance and use-effectiveness, such information is 
essential to guide the development and formulation of new microbicidal vaginal products. 
In this study, we explored vaginal spermicidal preparations containing nonoxynol-9 and 
the characteristics that influence user preferences for three formulations.  We also studied 
the risk of vaginal and cervical irritation associated with low to moderate use of products 
containing nonoxynol-9. 
 
Methods:  One hundred forty-five sexually active women were enrolled in five sites (Côte 
d'Ivoire, Zimbabwe, USA, and Thailand – two sites:  one rural, one urban) and asked to 
use three different vaginal spermicide preparations containing nonoxynol-9 (a gel, a film, 
and a suppository).  Each volunteer used each product for four weeks.  Structured 
interviews and clinical examinations were conducted at biweekly clinic visits.  Prior and 
to and following product use, women participated in focus group discussions to explore 
their knowledge, beliefs, and practices surrounding vaginal product use. 
 
Results:  Women enrolled in the New York City site were almost evenly divided in their 
preferences of the three formulations; most women enrolled in the Thai sites ranked the 
film as their preferred formulation (followed by the gel) due largely to the fact that it was 
easy to use, not too messy, and did not produce a lot of discharge; most of the women 
enrolled in Zimbabwe also ranked the film as their favorite, followed by the gel, because 
it was considered the least messy and provided the least amount of lubrication.  In Côte 
d'Ivoire, gel was the preferred formulation, followed closely by film. In general, the 
suppository was reported to be most messy, with the tendency to melt prior to insertion in 
hotter climates.  No significant irritation or lesions resulted from product use in any of the 
sites. Almost every woman reported that her partner was aware of, and supportive of, her 
participation in the study. 
 
Conclusion:  The formulation preferences of women should be considered in the 
development and introduction of vaginal microbicides:  the specific characteristics of 
vaginal products and their effect on sexual pleasure and communication will strongly 
determine the acceptability – and ultimately the use-effectiveness – of female-controlled 
STD-prevention methods. 
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Introduction 
=
There is an urgent need for safe, effective, and acceptable vaginal barrier methods for the 
prevention of sexually transmitted diseases (STDs), including HIV.  As product 
acceptability ultimately determines use-effectiveness, developing and introducing 
effective vaginal products for prevention of unwanted pregnancy and/or STD infection 
requires insight into users’ perspectives (Elias et al., 1996).  Research exploring the 
acceptability of woman-controlled barrier methods such as the female condom and the 
diaphragm (Do Lago et al., 1995; Gollub et al., 1995) has shown us that adoption of new 
methods is often a function of the kind of counseling that women receive with the new 
method, as well as having an opportunity to get accustomed to the method.  With the 
exception of two studies which looked at film, foam, foaming tablets, and suppositories 
in four countries in Latin America and East Africa (Steiner et al., 1995; Hira et al., 1995), 
little research has explored what constitutes the desirable characteristics of vaginal 
preparations among the diverse populations of women who would potentially use these 
products.  In addition to focusing on the kind of counseling that women receive, 
information regarding formulation preferences is essential for guiding the development of 
new vaginal preparations, as well as the broader application of existing spermicides. 
 
In this study, we sought to explore the characteristics of existing vaginal products – a gel, 
a suppository, and a film – that influence user preferences for various formulations.  
Because of the known irritating properties of nonoxynol-9 (Roddy et al., 1993; Kreiss et 
al., 1992) we also sought to further knowledge on the risk of irritation to the vagina and 
cervix potentially associated with low to moderate use of spermicidal products containing 
nonoxynol-9. 
 
Materials and Methods 
 
Study locations/sample 
 
To learn from a range of cultural norms relating to vaginal formulation preferences, we 
included a diverse group of study sites.  These included the Projet RETRO-CI in Abidjan, 
Côte d'Ivoire; Africa; the Siriraj Family Health Research Center in Bangkok, Thailand; 
the University of Zimbabwe in Chitungwiza, a township outside of Harare, Zimbabwe; 
the University of Khon Kaen in Northeastern Thailand; and the Columbia University 
School of Public Health in New York City.  A convenience sample of women was 
recruited at research centers via fliers and word of mouth or through health care facilities 
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(e.g., antenatal/MCH clinics in Zimbabwe).  To avoid the potential for irritation resulting 
from frequent use of nonoxynol-9 containing products, only women whose average coital 
frequency was one or fewer acts of intercourse per day were eligible for enrollment. 
Except for the Khon Kaen site, which recruited women from a village setting, all of the 
participants were drawn from urban populations.  
 
Products used 
 
Study participants used three different vaginal preparations (see Table 1), including the 
Vaginal Contraceptive Film® (Apothecus Pharmaceutical Corp., Oyster Bay, NY) 
containing 70 milligrams of nonoxynol-9; a vaginal suppository (Ortho Conceptrol® 
Vaginal Inserts) with 150 milligrams of nonoxynol-9, and a vaginal gel in a pre-filled 
applicator (Ortho Conceptrol® Gel) containing 200 milligrams of nonoxynol-9, both 
made by Advanced Care Products (Ortho Pharmaceutical Corp., Raritan, NJ).1  
 
Study procedure 
 
Women were counseled to use the products together with a male latex condom during 
each act of vaginal intercourse.  The study employed a crossover design where every 
participant used each product for a four-week period, during which time they were asked 
to report to the study center every two weeks for an interview and pelvic examination 
with speculum for visualization of the cervix and vagina.  Women’s experiences with 
product use, as well as any evidence of vulvar abnormality, cervical or vaginal discharge, 
cervicitis, or mucosal irritation, were coded on the case record forms.  Characteristics of 
vaginal discharge recorded included color, quantity, odor, and pH.  Cervical discharge 
============================================
1 In our lab we found that only 100-120mg was actually dispensed from the applicator.  =
Table 1 
Products Used in the Study 
 
Product used Nonoxynol-9 
Apothecus Vaginal Contraceptive Film 70 mg 
Ortho Conceptrol Gel 200 mg1 
Ortho Conceptrol Vaginal Inserts 150 mg 
==
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was considered abnormal when described as purulent, mucopurulent or bloody.  We 
defined cervicitis as observation of inflammation of the cervical mucous membrane.  
Using standard statistical software (SPSS Version 6.1), we compared symptomatic 
reports with clinical signs using X2 tests and Fisher’s exact texts.  Significance was 
designated as p<0.05.  In many cases, however, the numbers were very small and formal 
statistical comparisons were not attempted. 
 
Prior to and following product use, all women participated in focus group discussions and 
structured interviews to assess their knowledge, practices, and preferences regarding each 
vaginal formulation.  Women were asked to record each act of intercourse in a coital log 
where they also noted whether the study product and/or condoms were used. 
 
Results 
 
Socio-demographic characteristics 
 
The mean age of the 145 women participating in this study ranged from 25 in Abidjan to 
37 in Khon Kaen (see Table 2).  In the two Thai sites, and in Chitungwiza,  nearly all of 
the women were married; whereas in Abidjan and New York City married women 
constituted only 17 and 42 percent of the sample, respectively.  The low figure in Abidjan 
Table 2 
Selected Characteristics of Study Populations 
 
 Abidjan, 
Côte 
d’Ivoire 
n = 31 
 Bangkok, 
Thailand 
 
n = 25 
Chitungwiza, 
Zimbabwe 
 
n = 22 
Khon 
Kaen, 
Thailand 
n = 36 
New York 
City, 
USA 
n = 31 
Age (mean) 25 30 32 37 30 
Married (%) 17% 100% 96% 100% 42% 
Coital frequency in 
the month preceding 
the study (mean) 
4 5 18 5 8 
Parity (mode) 2 1 4 3 1 
Ever tried to 
convince partner to 
use condoms (%) 
63% 40% 79% 27% 97% 
Always uses 
condoms with 
partner (%)  
0% 0% 9% 0% 55% 
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may reflect a high prevalence of unofficial—or commonlaw—marriage in Côte d’Ivoire. 
The mean coital frequency in the month prior to the study ranged from a low of four in 
Abidjan to a high of 18 in Chitungwiza.  Parity ranged from one in New York City and 
Bangkok to a high of four in Chitungwiza.  
 
Vaginal product and condom use history  
 
There was considerable variation in women’s previous experience with vaginal products, 
as reflected in women’s prior use of spermicidal products or vaginal tampons.  When 
asked why they might use vaginal products in the future, women from the four sites that 
reported data for this question stated that the primary reasons would be for protection 
from infection alone (40 percent), protection from pregnancy alone (13 percent), or both 
(44 percent).2. 
 
A significant proportion of women in New York and the two African sites had tried in the 
past to convince their regular partners to use condoms (see Table 2).  Consistent condom 
use, however, was reported by only 55 percent of women in New York City, nine percent 
in Chitungwiza, and no women in Abidjan, Bangkok, or Khon Kaen.3  Many women 
reported that their partners refused to use condoms because they did not want to 
contracept.  During the study, the percentage of women whose partners used condoms 
during use of the study product was low, and was about the same regardless of which 
product the woman was using (26, 29, and 30 percent, respectively, for film, gel and 
suppository). 
 
Partner’s knowledge of product use 
 
When asked whether they were able to use the study products without their partner’s 
knowledge, most women in this study reported that they preferred to inform their partners 
that they were using vaginal products—both in the context of the study, and in a 
hypothetical, future framework (see Table 3). Only roughly one-quarter of the women 
chose not to inform their partners, with even lower percentages in the Thai sites.  Most 
women preferred telling their partners at the outset of the study, in case they or their 
============================================
2The Khon Kaen site did not report data for this question and 3% of participants at the other four sites were 
“not sure” or had missing data for this question.=
3New York site investigators felt that, given the probability that participants volunteering for this study are 
particularly interested in barrier prevention methods, the consistent condom use levels reported for New York 
may actually be substantially higher than in the general population.=
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partners subsequently experienced problems with a particular product.  In Chitungwiza 
women were particularly concerned about having to explain the presence of a product if 
her partner detected it.  Others said that their partners supported them in using vaginal 
products, especially if vaginal product use was perceived to enhance sexual frequency or 
pleasure.  There was no correlation between formulation preferences and the desire to 
hide product use from one’s partner. 
 
Experience with study products 
 
In most cases, women found the suppository to be the messiest and, therefore, least 
desirable of the formulations: it tended to melt at the tropical ambient temperatures of 
several of the study sites and, consequently, needed refrigeration in order to prevent 
melting prior to insertion (see Table 4).   
 
 
As with the earlier three-country study (Steiner et al., 1995), film was the overall 
preferred formulation in three of the five sites in that it was considered to be the most 
Table 3 
Able to Use Product Without Partner’s Knowledge 
 
 Abidjan, Côte 
d’Ivoire 
n = 31 
Bangkok, 
Thailand 
n = 25 
Chitungwiza, 
Zimbabwe 
n = 22 
Khon Kaen, 
Thailand 
n = 36 
New York 
City, USA 
n= 31 
Film 40% 0% 20% 3% 15% 
Gel 25% 4% 17% 14% 27% 
Suppository 20% 0% 14% 4% 26% 
Table 4 
Women's Preferences for Products, by Site 
 
 Abidjan, Côte 
d’Ivoire 
n = 31 
Bangkok, 
Thailand 
n = 25 
Chitungwiza, 
Zimbabwe 
n = 22 
Khon Kaen, 
Thailand 
n = 36 
New York 
City, USA 
n = 31 
 
 
All sites 
Product liked 
most  
gel film film film gel film 
Product liked 
least 
suppository suppository gel suppository film suppository 
==
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"natural" and was liked by many of the women’s partners.  Women in Khon Kaen, 
Bangkok, Chitungwiza, and Abidjan all stated that they liked the film especially, due to 
the fact that it left the vagina feeling “tight” or “fit.”  Indeed, preferences were often 
related to perceptions of “wet” versus “dry” (see Table 5).  Due to the fact that the film 
has a tendency to stick to damp fingers, however, it was considered the most difficult to 
insert by many users.  For those women who experienced initial difficulty in inserting the 
film, however, their confidence and ability to use this product increased substantially with 
experience and supportive counseling. 
 
The most preferred formulation in New York and Abidjan, the gel was generally deemed 
the easiest to apply and had an advantage of not requiring a waiting time following 
insertion.  It was also preferred by older women in the Khon Kaen site specifically 
because of its lubricant qualities.  Many other women, however, complained of excessive 
lubrication and “runniness” following intercourse with the gel product. 
 
We found that preferences after actual use did not correlate well with those expressed in 
hypothetical pre-use focus group discussions, especially in those sites where women had 
little prior experience with vaginal product use.  For example, some participants were 
“intrigued” by unfamiliar products and predicted that they would like them best (e.g., 
Table 5 
Selected Product Characteristics Described by Study Participants 
 
 Advantages Disadvantages 
Film Least messy  
Easy to conceal/dispose of 
Can’t feel it when it’s in 
Enhanced sexual pleasure 
Tends to stick to fingers during 
application 
Long wait for it to melt prior to 
intercourse 
Gel with 
applicator  
No waiting time before product is 
effective 
Applicator precludes need to touch 
oneself directly 
Enhanced sexual pleasure 
Often runny 
Applicator painful to use 
Applicator difficult to conceal/ 
dispose of 
Suppository Lubricating 
Small, easy to conceal/dispose of 
Tendency to melt at warm ambient 
temperatures 
Creates a lot of messy discharge 
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women in New York thought the film was wonderfully small, and women in Bangkok 
were quite taken with the gel’s applicator).  On the other hand, women’s hypothetical 
preferences were often informed by what they were already familiar with.  For example, 
in Khon Kaen women thought that they would like the suppository because they were 
familiar with the use of suppositories for the treatment of vaginal yeast infections whereas 
they had never seen a vaginal film or applicator before.  Following actual product use, 
however, the characteristics that women often found interesting, familiar or appealing no 
longer mattered in their overall ranking of the product.   
 
In discussions both before and after product use, women felt strongly that vaginal 
products should be formulated so as to not interfere with sexual pleasure.  In fact, in three 
of the sites (Abidjan, Chitungwiza, and Khon Kaen), women favored some products 
because they enhanced sexual pleasure.  In general, reports of the partners’ and women’s 
reactions to the different products reinforced each other.    
 
Disposal was a major concern in Zimbabwe where women reported burning the used 
applicators and packaging to avoid having neighbors and/or children find evidence of 
their use.  Similarly, participants in Khon Kaen expressed concern about their need to 
keep the suppositories in the refrigerator where other family members could see them. 
 
There were often trade-offs regarding product characteristics.  For example, some women 
liked the ease of insertion of the gel, but also felt it was too messy.  Several of these 
women compensated for this by decreasing the volume of gel they applied.  Some women 
reported that use of certain products resulted in increased frequency of intercourse.  
However, overall product preference was not a function of coital frequency.  Of interest, 
women in some sites either perceived that the products had medicinal or hygienic effects 
(Chitungwiza) or reported an improvement in chronic genital symptoms, such as pruritus, 
after product use (Khon Kaen).  Despite specific drawbacks to each formulation, study 
participants expressed great interest in the products, and many stated that they would 
continue to use any of them – even their least preferred formulations – if they were 
available and approved for STD prevention. 
 
There was considerable variation between sites in regard to reports of “some,” 
“moderate,” and “high” levels of discomfort or irritation due to product use (see Table 6). 
Women in most sites reported the least discomfort in using the film, and the most in gel 
use. 
==
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Analysis of clinical observations, however, indicates that irritation of the cervix or vagina 
was fairly uncommon (see Table 7).  Among women’s reports of symptoms and clinical 
findings for each product use group, there was no association between clinical irritation 
and reported symptoms (Fisher’s exact test for intervals of gel use (p=1.00), for intervals 
of film use (p=0.43), or for intervals of suppository use (p=0.07)).  Despite differences in 
partners’ preferences, which were reflected in women’s own stated preferences, reported 
partner irritation was fairly low across the products (six, eleven, and nine percent of male 
partners reported irritation with film, gel, and suppository, respectively).  
 
Table 6 
Reported Discomfort or Irritation with Product Use 
 
 Abidjan, 
Côte 
d’Ivoire 
n = 31 
Bangkok, 
Thailand 
 
n = 25 
Chitungwiza, 
Zimbabwe 
 
n = 22 
Khon Kaen, 
Thailand 
n = 36 
New York 
City, USA 
 
n = 31 
All sites 
 
n = 145 
Film 4% 0% 5% 3% 7% 4% 
Gel 0% 21%  11% 36% 19% 20% 
Suppository 5% 21% 5% 15% 11% 12% 
 
Table 7 
Number of Clinical Signs Observed/Total Number of Clinical Visits 
 
 Vulvar 
abnormality 
Vaginal 
discharge 
Cervical 
dischargeb 
 
Cervicitis
Pain on bi-weekly 
manual exam 
 
Total  
Baselinea 3/145 4/145 4/145 0/145 3/145 14/145 
Film 3/290 3/290 11/290 1/290 1/290 19/290 
Gel 1/290 5/290 9/290 1/290 0/290 16/290 
Suppository 2/290 0/290 8/290 0/290 0/290 10/290 
aClinical observations at enrollment. 
bIncluded cervical discharge described as “purulent,” “mucopurulent,” and “bloody.” 
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Discussion 
 
Overall, we observed considerable variation in users’ perspectives and formulation 
preferences both within and between sites.  As with the earlier three-country study 
(Steiner et al., 1995), film was the overall preferred formulation. Nevertheless, cultural 
norms affected specific preferences for relative “dryness” of the formulations, and 
generational differences, even within the same site, influenced the degree of lubrication 
considered desirable.  This suggests that, in the development of new vaginal 
microbicides, multiple products will be required to meet the needs of all users.  
 
Because of the wide range of cultural norms governing desirable fertility levels, and given 
women’s differing personal expectations and needs, study participants expressed 
considerable interest in the possibility of using a vaginal microbicide that would be non-
spermicidal.  Although it could be argued that most women, at any given point in their 
lives, probably do not want to become pregnant, it can also be noted that nearly every 
woman, at some point in her life, does want to conceive – preferably without putting 
herself at risk of infection.  Ideally, both contraceptive and non-contraceptive products 
should be pursued in research and development efforts. 
 
Storage, application and disposal issues must be taken into consideration as well.  With 
regard to packaging, many study participants commented favorably on the ease with 
which they were able to conceal the film, both in storage and in disposal.  It will be 
important to consider the amount of excess “packaging” that characterizes a given 
product.  In almost every site, at least some of the women reported that they and their 
partner enjoyed using the products because their use was seen as sexy:  for those women, 
a product that is perceived as enhancing sexual pleasure is more likely to be used.  In a 
few sites, women felt that the products “cured” them of various vaginal complaints – 
even though they were told what the products were for.  Clearly, the “trade-offs” between 
promoting a product for disease prevention versus increasing sexual pleasure or vaginal 
health must be further explored.   
 
As noted above, and as has been observed in other low-frequency studies of nonoxynol-9 
use (Feldblum, 1996), the numbers of women reporting any kind of discomfort were very 
low, as were the number of women with clinical signs of irritation.  Although women 
were encouraged to come in to the clinic at any time they experienced discomfort with 
any of the products, we observed that women only came in for their scheduled two-week 
visits.  We must therefore be cautious in drawing conclusions about a lack of correlation 
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between clinical signs and symptoms, given that women may indeed have had clinical 
signs of irritation at the time they were experiencing symptoms that had cleared up by the 
time they came in for their examination.  Such a lack of correlation in lower frequency 
use of nonoxynol-9 was also observed in a previous study (Roddy et al., 1993).  
 
Women in this study, many of whom were family planning clients or hospital employees, 
expressed little interest in covert methods.  In fact, many of the participants stated that 
they “wouldn’t dream” of hiding product use from their partner.  Women in partnerships 
characterized by higher levels of violence, coercion, or commerce, however, might have a 
greater need for products that could be used without a partner's knowledge.  It is also 
possible that covert use would be more common outside the context of a research study.  
Despite the fact that products such as those employed in the study have been available in 
several of the study sites as over-the-counter spermicides for many years, the frequent 
clinic visits and intense clinical observations of this study gave some participants the 
impression of “experimental” product use.  A few women mentioned in the focus group 
discussions that their partners expressed some concern about the nature of such 
experimentation.  The study may have thus introduced a concern for gaining partner 
consent that may not exist when products are commercially available.  
 
For this group of women, partner’s perceptions of product characteristics and the 
dynamics of partner communication proved to be very important.  It is therefore critical to 
explore men’s attitudes and beliefs regarding vaginal microbicide use more explicitly in 
future studies. 
 
A greater understanding of users” perspectives and preferences will help in the preclinical 
development of new vaginal products:  information on how, why and whether women 
will use new products is essential to help us to create a product that will actually be 
accepted and used.  Yet, as evident in other studies (Do Lago, 1995; Gollub, 1995), there 
is also a need to consider the counseling and information needs of potential users and the 
important role of service providers.  Ultimately, changing the products may only be one 
half of the equation:  we must also learn more about the best ways to introduce and 
support products within service delivery programs. 
 
Given the trade-offs that women and their partners face in using vaginal products, we 
must also learn more about the dynamics of actual product use.  Few people will adhere 
strictly to package instructions, especially when using products outside the context of a 
clinical study.  For instance, if women are going to decrease the volume of vaginal 
applications because the product is otherwise too messy, we must know this in order to 
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ensure that dosage is adequate under real use conditions.  As with other user-controlled 
methods, product acceptability is a central determinant of use-effectiveness.  Ultimately, 
the development and introduction of any new vaginal microbicide will need to take into 
careful consideration the kinds of findings of this and similar studies, in order to ensure 
that women are armed with the best information and products available to protect 
themselves from infection.    
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